Evidence map›Paper›PMID 34177521›Full record

ArticleCase reports in oncology

Personalized Approach to Tissue and Liquid Biopsy after Failure of First-Line EGFR-TKIs: Is There an Issue When Tissue Is Not the Issue? A Case Series.

Daliborka Bursac, Bojan Zarić, Tomi Kovačević, Vladimir Stojšić, Anastasios Vagionas, Ioannis Boukovinas, Kosmas Tsakiridis, Christoforos Kosmidis, Konstantinos Sapalidis, Konstantinos Romanidis and 5 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Cryobiopsy for pneumonitis diagnosis in NSCLC immunotherapy.Respiratory medicine case reports · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 10 institutions in 2 countries.

Daliborka BursacFaculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
Bojan ZarićFaculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
Tomi KovačevićFaculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
Vladimir StojšićFaculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
Anastasios VagionasOncology Department, General Hospital of Kavala, Kavala, Greece.
Ioannis BoukovinasOncology Department, "Bioclinic" Private Department, Thessaloniki, Greece.
Kosmas TsakiridisThoracic Surgery Department, "Interbalkan" European Medical Center, Thessaloniki, Greece.
Christoforos KosmidisThird University General Hospital, "AHEPA" University Hospital, Thessaloniki, Greece.
Konstantinos SapalidisThird University General Hospital, "AHEPA" University Hospital, Thessaloniki, Greece.
Konstantinos RomanidisSecond Department of Surgery, General University Hospital of Alexandroupolis, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
Nikolaos CourcoutsakisRadiology Department, University General Hospital of Alexandroupolis, Democritus University of Thrace, Medical School of Health Sciences, Alexandroupolis, Greece.
Dimitris MatthaiosOncology Department, General Hospital of Rhodes, Rhodes, Greece.
Paul ZarogoulidisThird University General Hospital, "AHEPA" University Hospital, Thessaloniki, Greece.
Chrysanthi SardeliDepartment of Pharmacology and Clinical Pharmacology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Vanesa SekerusFaculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
University of Novi Sad · RSAHEPA University Hospital · GRInstitute for Pulmonary Diseases of Vojvodina · RSPolyclinic General Hospital · GRAristotle University of Thessaloniki · GRDemocritus University of Thrace · GRGeneral Hospital of Rhodes · GRInterbalkan Medical Center · GRTechnological Educational Institute of Eastern Macedonia and Thrace · GRUniversity Hospital of Alexandroupolis · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Traditionally, tissue availability from rebiopsy is a prerequisite for adequate sequencing of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in therapy for advanced-stage lung cancer. Tissue biopsy truly is the gold standard for genetic analyses, but in some cases, such as with inadequate localization of the lesion or a patient's inadequate performance status, comorbidities, or unwillingness to undergo an invasive procedure, liquid biopsy-based ctDNA analysis can be a noninvasive alternative approach. However, in some cases the gold standard might not shine that much. It is known that tumor heterogeneity or an inadequate amount of tissue might significantly interfere with the results of testing. In this paper, we present cases of patients with a negative tissue biopsy but a positive liquid biopsy which identified coexisting T790M mutation. These results enabled adequate sequencing and treatment with third-line EGFR-TKIs. Such possibilities stress the need to individualize testing for driver mutations in cases where it is clinically highly indicated.

Indexed as

Liquid biopsyOsimertinibT790M mutationTissue biopsy

Identifiers

PMID34177521
PMCPMC8215970
OpenAlexW3163626566

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.